Volitionrx (VNRX) EBITDA (2012 - 2026)

Volitionrx (VNRX) has reported EBITDA for 11 consecutive years, with -$4.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 34.01% year-over-year to -$4.2 million; the trailing twelve-month figure through Jun 2026 stood at -$20.4 million (up 13.19% YoY), and the FY2025 full-year result was -$21.7 million, up 19.56% from the prior year.
• EBITDA grew to -$4.2 million in Q2 2026 per VNRX's latest filing, from -$4.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.2 million in Q2 2026 and bottomed at -$9.5 million in Q2 2023.
• Historically, EBITDA has averaged -$7.1 million across 5 years, with a median of -$7.7 million in 2022.
• The sharpest annual moves came in 2022 and 2025: EBITDA slumped 37.26% in 2022, then jumped 34.14% in 2025.
• Over 5 years, EBITDA stood at -$8.0 million in 2022, then decreased by 9.11% to -$8.7 million in 2023, then soared by 33.86% to -$5.8 million in 2024, then gained by 16.66% to -$4.8 million in 2025, then rose by 13.75% to -$4.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$4.2 million, -$4.8 million, and -$5.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.